Decoding LNTH Stock – A Market Analysis

By Emilio Sanchez • Thursday, September 26 15:12 • Permanent Link

Lantheus logged a -2.9% change during today's afternoon session, and is now trading at a price of $104.78 per share. The S&P 500 index moved 0.0%. LNTH's trading volume is 707,839 compared to the stock's average volume of 1,066,863.

Lantheus trades -27.51% away from its average analyst target price of $144.55 per share. The 11 analysts following the stock have set target prices ranging from $125.0 to $175.0, and on average have given Lantheus a rating of buy.

Anyone interested in buying LNTH should be aware of the facts below:

Lantheus's current price is 200.6% above its Graham number of $34.86, which implies that at its current valuation it does not offer a margin of safety
Lantheus has moved 55.3% over the last year, and the S&P 500 logged a change of 33.1%
Based on its trailing earnings per share of 6.08, Lantheus has a trailing 12 month Price to Earnings (P/E) ratio of 17.2 while the S&P 500 average is 28.21
LNTH has a forward P/E ratio of 14.6 based on its forward 12 month price to earnings (EPS) of $7.2 per share
The company has a price to earnings growth (PEG) ratio of 0.44 — a number near or below 1 signifying that Lantheus is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 7.08 compared to its sector average of 3.69
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
Based in Bedford, the company has 834 full time employees and a market cap of $7.27 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.